{
    "response": "**Overall Treatment Decision:** Yes\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Urgent neurology admission and close neurological observation\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Brainstem lesions can deteriorate rapidly and threaten airway, breathing or consciousness Patient has ataxia and hemiparesis with high fall risk and needs supervised mobility Allows expedited completion of MRI, vascular imaging and CSF studies\n\n*   **Treatment:** Symptomatic management of diplopia with eye patch or occlusive lens\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Reduces disabling double vision and improves safety for ambulation Low-risk intervention that does not interfere with later diagnostic procedures\n\n*   **Treatment:** Early physiotherapy and occupational therapy for gait, balance and upper limb function\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Left spastic hemiparesis and ataxia predispose to contractures and falls Early rehabilitation improves long-term functional outcomes and independence\n\n*   **Treatment:** High-dose intravenous methylprednisolone for suspected demyelinating brainstem relapse\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Should be started once MRI and CSF confirm an active demyelinating lesion and exclude alternative diagnoses such as infarct, tumour or infection Avoids unnecessary steroid exposure and potential side effects if the aetiology is non-demyelinating\n\n*   **Treatment:** Initiation of disease-modifying therapy for multiple sclerosis\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Requires that formal diagnostic criteria for multiple sclerosis are met based on clinical and MRI evidence Choice of agent needs multidisciplinary discussion, baseline safety blood tests and patient counselling regarding risks and benefits\n\n*   **Treatment:** Vascular-specific therapy if indicated (antiplatelet therapy for ischaemic midbrain stroke or endovascular/neurosurgical repair for a posterior communicating artery aneurysm)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Should only be instituted if imaging demonstrates ischaemic infarction or an aneurysm/vascular malformation Prevents inappropriate antithrombotic use in demyelinating, neoplastic or haemorrhagic lesions and allows tailored intervention based on vascular findings\n\n\ntreatments = [{\"treatment\": \"Urgent neurology admission and close neurological observation\", \"timing\": \"Start Now\", \"reasons\": [\"Brainstem lesions can deteriorate rapidly and threaten airway, breathing or consciousness\", \"Patient has ataxia and hemiparesis with high fall risk and needs supervised mobility\", \"Allows expedited completion of MRI, vascular imaging and CSF studies\"]}, {\"treatment\": \"Symptomatic management of diplopia with eye patch or occlusive lens\", \"timing\": \"Start Now\", \"reasons\": [\"Reduces disabling double vision and improves safety for ambulation\", \"Low-risk intervention that does not interfere with later diagnostic procedures\"]}, {\"treatment\": \"Early physiotherapy and occupational therapy for gait, balance and upper limb function\", \"timing\": \"Start Now\", \"reasons\": [\"Left spastic hemiparesis and ataxia predispose to contractures and falls\", \"Early rehabilitation improves long-term functional outcomes and independence\"]}, {\"treatment\": \"High-dose intravenous methylprednisolone for suspected demyelinating brainstem relapse\", \"timing\": \"Delay\", \"reasons\": [\"Should be started once MRI and CSF confirm an active demyelinating lesion and exclude alternative diagnoses such as infarct, tumour or infection\", \"Avoids unnecessary steroid exposure and potential side effects if the aetiology is non-demyelinating\"]}, {\"treatment\": \"Initiation of disease-modifying therapy for multiple sclerosis\", \"timing\": \"Delay\", \"reasons\": [\"Requires that formal diagnostic criteria for multiple sclerosis are met based on clinical and MRI evidence\", \"Choice of agent needs multidisciplinary discussion, baseline safety blood tests and patient counselling regarding risks and benefits\"]}, {\"treatment\": \"Vascular-specific therapy if indicated (antiplatelet therapy for ischaemic midbrain stroke or endovascular/neurosurgical repair for a posterior communicating artery aneurysm)\", \"timing\": \"Delay\", \"reasons\": [\"Should only be instituted if imaging demonstrates ischaemic infarction or an aneurysm/vascular malformation\", \"Prevents inappropriate antithrombotic use in demyelinating, neoplastic or haemorrhagic lesions and allows tailored intervention based on vascular findings\"]}]"
}